Scribe Therapeutics, a biotech focused on cardiovascular disease, priced its IPO at the high end, raising $129 million with a market valuation of $273 million. This IPO was one of five public offerings last week, including four SPACs. Looking ahead, two large IPOs and a direct listing are scheduled, with additional smaller deals possible. Market analysts expect research reports on three companies and anticipate five lock-up periods to expire soon, which may influence stock availability and prices.
Sezzle Inc. reported record first-quarter results for fiscal year 2026, driven by growth in subscribers and purchase frequency. The fintech company, known for its Buy Now, Pay Later services, achieved new highs in gross merchandise volume, revenue, a...
Despite Ripple's expanding business and adoption by banks, XRP's price is predicted to remain in a prolonged sideways trend until August 2028. Technical analysis using Bollinger Bands suggests a repeat of the 2022-2024 accumulation cycle, indicating ...
Boyd Gaming Corporation reported Q2 results with strong performance in regional operations driven by customer trends and capital investments. However, weak results in Las Vegas continue to drag overall earnings. Disruptions at The Suncoast property a...
Peter Kendall has stepped down as Interim CEO of ARCpoint Inc. after completing his 90-day mandate to assess the company's business model, technology platform, and strategic direction. He provided recommendations to the Board, which is now evaluating...
BOK Financial reported record loan production and excellent credit metrics in Q2, leading to an upward revision of its full-year 2026 guidance. The stock trades at about 13.6 times forward earnings per share, within the fair value range of $140 to $1...
